Apnimed’s star sleep apnea asset has hit the latest landmark on its march down victory road. | Apnimed’s star sleep apnea ...

Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep ...

Allison Stange lost 40 pounds since starting Zepbound in April 2024, improving both her blood pressure and sleep apnea. Now ...

Sleep apnea could be costing you brain power and increasing your risk of dementia and Alzheimer's disease, a new study says.

A previous version of this report failed to reflect that the scientific name tirzepatide refers to Zepbound. It has been corrected. A study of two blockbuster weight-loss drugs showed that users ...

While the primary target for these medication is weight loss, it’s not the only metric by which the drugs should be evaluated ...

Medicare recipients suffering from obesity must pay out of pocket for weight loss drugs like Wecovy and Zepbound.

In a 72-week trial, people taking Zepbound lost 50 pounds on average, compared with about 33 pounds for people taking Wegovy.

Zepbound outperformed Nordisk's Wegovy in terms of weight loss, solidifying Lilly's leadership in the anti-obesity drug ...